NKTR · Nektar Therapeutics
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. |
Common Stock
|
5,681 |
| 2026-06-17 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $61.22 to $62.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
4,500 |
| 2026-06-17 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $60.22 to $61.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
5,500 |
| 2026-06-16 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $59.35 to $60.33 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
5,303 |
| 2026-06-16 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $60.37 to $61.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
4,697 |
| 2026-06-15 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
5,538 |
| 2026-05-19 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
444 |
| 2026-05-19 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
199 |
| 2026-05-15 | Rubinstein Linda M |
Interim Chief Financial Ofcr |
Other↑
|
No Securities Owned
|
0 |
| 2026-02-18 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
423 |
| 2026-02-18 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
180 |
| 2026-01-20 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025. This transaction was executed in multiple trades at prices ranging from $35.17 to $36.23 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
3,867 |
| 2025-12-22 | Zalevsky Jonathan |
Chief R&D Officer |
Award↑
Filing footnotes — Stock Option (Direct)
Stock options vest over four years from the date of grant, (December 22, 2025) in substantially equal monthly installments based on continued service. |
Stock Option
|
25,000 |
| 2025-12-22 | ROBIN HOWARD W |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Direct)
Stock options vest over four years from the date of grant, (December 22, 2025) in substantially equal monthly installments based on continued service. |
Stock Option
|
86,667 |
| 2025-12-22 | Zalevsky Jonathan |
Chief R&D Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs vest over four years from the date of grant (December 22, 2025) in substantially equal quarterly installments based on continued service. |
Common Stock
|
6,250 |
| 2025-12-22 | ROBIN HOWARD W |
Director, President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs vest over four years from the date of grant (December 22, 2025) in substaintially equal quarterly installments based on continued service. |
Common Stock
|
21,667 |
| 2025-11-25 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,157 |
| 2025-11-25 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
2,207 |
| 2025-11-25 | Wilson Mark Andrew |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). |
Common Stock
|
630 |
| 2025-11-21 | Zalevsky Jonathan |
Chief R&D Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. |
Common Stock
|
2,666 |
| 2025-11-21 | Wilson Mark Andrew |
Chief Legal Officer |
Award↑
Filing footnotes — Stock Option (Direct)
These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. |
Stock Option
|
3,400 |
| 2025-11-21 | ROBIN HOWARD W |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Direct)
These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. |
Stock Option
|
12,170 |
| 2025-11-21 | ROBIN HOWARD W |
Director, President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. |
Common Stock
|
7,110 |
| 2025-11-21 | Zalevsky Jonathan |
Chief R&D Officer |
Award↑
Filing footnotes — Stock Option (Direct)
These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. |
Stock Option
|
4,766 |
| 2025-11-21 | Wilson Mark Andrew |
Chief Legal Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). |
Common Stock
|
1,903 |
| 2025-09-30 | CHESS ROBERT |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. |
Stock Option
|
8,000 |
| 2025-09-30 | Ajer Jeffrey Robert |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. |
Stock Option
|
8,000 |
| 2025-09-30 | GREER R SCOTT |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. |
Stock Option
|
8,000 |
| 2025-09-30 | WHITFIELD ROY A |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. |
Stock Option
|
8,000 |
| 2025-09-30 | Brainard Diana |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. |
Stock Option
|
8,000 |
| 2025-09-09 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $45.00 to $45.41 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
2,100 |
| 2025-09-09 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $47.02 to $47.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
2,156 |
| 2025-09-09 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $48.00 to $48.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,210 |
| 2025-09-09 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $46.05 to $46.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,200 |
| 2025-09-05 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $37.50 to $38.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
3,304 |
| 2025-09-05 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $39.50 to $40.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,136 |
| 2025-09-05 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $38.50 to $39.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
2,226 |
| 2025-09-04 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $33.08 to $34.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
432 |
| 2025-09-04 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $32.08 to $33.02 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
793 |
| 2025-09-04 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $33.02 to $33.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,496 |
| 2025-09-04 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $34.05 to $34.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
613 |
| 2025-09-04 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $34.09 to $34.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
189 |
| 2025-09-04 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $32.01 to $32.99 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,923 |
| 2025-09-04 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $35.35 to $36.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,134 |
| 2025-09-04 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $35.48 to $36.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
307 |
| 2025-09-02 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.30 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,500 |
| 2025-09-02 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.28 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Common Stock
|
485 |
| 2025-08-19 | Zalevsky Jonathan |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
Common Stock
|
725 |
| 2025-08-19 | ROBIN HOWARD W |
Director, President & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
Common Stock
|
1,573 |
| 2025-08-19 | ROBIN HOWARD W |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Direct)
These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements). |
Stock Option
|
86,666 |